Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
about
Abacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infectionDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studySimplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialEarly changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovirInflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems.Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.Biomarkers and HIV-associated cardiovascular disease.Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.Management of HIV infection in treatment-naive patients: a review of the most current recommendations.Epidemiology and management of antiretroviral-associated cardiovascular disease.Relaxation effect of abacavir on rat basilar arteries.Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclaseIs there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis.Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women.Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimensInflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirRole of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.Abacavir and lamivudine for the treatment of human immunodeficiency virus.HIV medications: an update and review of metabolic complications.Ageing with HIV: a multidisciplinary review.Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials.HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.
P2860
Q24235506-C6330591-2EDB-4026-A0C9-1CFDB300120BQ28543075-FA60B4FE-2FC6-4323-9A9B-E589F34273AEQ33604322-1EF90268-56CA-4588-BB6A-36357326EB92Q33812049-6323DDC5-679C-400F-96E8-43751DA6E2C1Q33926735-A0657ED8-78AC-4E94-A451-FE1AE82D0289Q34039680-F6AC763D-51FD-4BB2-98F3-DB946603BBB7Q34335486-CD837F8D-1746-47E9-A640-B388A0A28AC9Q34796153-0DC237E7-98CC-466A-9D08-447CFC7CE29BQ35188723-0E59A7CD-DBB5-4331-90C2-03B89CCEFEE6Q35338096-E9A037F2-3BB2-46E4-AD1A-1212B6E04AD7Q35597616-935459ED-2A99-44EE-809D-02F21B793D54Q35737682-A84A2A13-825D-4152-9AD0-7B12E6EBF5BEQ35977313-4FEF4DDA-5D5A-49D9-9081-6DD5511E86C9Q36116238-FFCF10EA-B1D2-4F81-A97F-93DF448FC6F1Q36220644-FF767D6B-DB4D-49D2-B7F8-1F3D47CD2416Q36404094-894FE1B0-B7B6-4D0E-9ECE-AA76FD68DAEFQ36419549-93D2BBF9-DDB4-46C6-B8B1-739CC3B29A0CQ36578046-A7F52DC3-BC47-4182-9F3E-EB83A3D09116Q36974022-67B5261C-D8C4-409D-A1C1-048788A3AC02Q37279429-3551EE19-9C3F-4F2B-BA48-F2D340FFC715Q37344527-B4D129CF-8C03-460E-8DBE-B5EC25E4C6A4Q37542914-E7444C53-D6E3-42A8-A9A3-4CC2B85F9EECQ37905058-BAA86A3D-9110-4A0F-BDD2-46516E9BB599Q37981602-6507211A-A3E4-45B3-A117-D8EA80F5C888Q38490362-6CC039F5-DB58-4CC8-940C-CB6729295F84Q42609996-B161E9ED-5DFF-4C3F-AF76-3F99392CBE9CQ48856213-01698FED-519F-4E23-961C-6DA97FF8CDF6Q55001110-B06FAB8C-3C17-4C38-B4E8-2D6CB3200417Q55210420-9C30220B-EC1A-467F-B46D-C7F207626CE0
P2860
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Abacavir-based therapy does no ...... th cardiovascular dysfunction.
@en
Abacavir-based therapy does no ...... th cardiovascular dysfunction.
@nl
type
label
Abacavir-based therapy does no ...... th cardiovascular dysfunction.
@en
Abacavir-based therapy does no ...... th cardiovascular dysfunction.
@nl
prefLabel
Abacavir-based therapy does no ...... th cardiovascular dysfunction.
@en
Abacavir-based therapy does no ...... th cardiovascular dysfunction.
@nl
P2093
P1433
P1476
Abacavir-based therapy does no ...... th cardiovascular dysfunction.
@en
P2093
BICOMBO Study Team
Daniel Podzamczer
Esteban Martínez
Félix Gutiérrez
Ignacio Pérez
Josep Mallolas
José M Gatell
Judit Pich
María Larrousse
Montserrat Loncá
P356
10.1097/QAD.0B013E32833562C5
P407
P577
2010-01-01T00:00:00Z